LLY

987.98

+2.24%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

LLY

987.98

+2.24%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

MRK

112.41

+0.96%↑

Home・Akcijų sąrašas・Johnson and Johnson

Johnson and Johnson

Uždarymo kaina

SektoriusSveikatos priežiūra

224.37 1.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

221.4

Max

227.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	119M 5.2B
Pardavimai	-502M 24B
P/E Sektoriaus vid.	25.629 51.415
Pelnas, tenkantis vienai akcijai	2.7
Dividendų pajamingumas	2.35
Pelno marža	21.756
Darbuotojai	138,200
EBITDA	182M 6.4B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+19.55% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.35% 2.34%
Kitas uždarbis	2026-07-15
Kitas dividendų mokėjimo data	2026-06-09
Kita Ex Dividend data	2026-05-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-40B 533B
Ankstesnė atidarymo kaina	223.02
Ankstesnė uždarymo kaina	224.37

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

154.93 / 155.895 Palaikymas ir pasipriešinimas

Johnson and Johnson Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 13:27; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-22 11:27; UTC

Uždarbis

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

2026-04-14 19:38; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 14:13; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 12:57; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 11:19; UTC

Uždarbis

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

2026-04-14 10:34; UTC

Uždarbis

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

2026-04-14 10:20; UTC

Rinkos pokalbiai

Uždarbis

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

2026-04-14 10:20; UTC

Rinkos pokalbiai

Uždarbis

J&J's Tremfya Sales Continue to Surge -- Market Talk

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson 1Q Adj EPS $2.70 >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson: New Treatment for Bladder Cancer Inlexzo Is Outperforming All Recent Launches Based on Unique Patients Treated in First 6 Months of Approval >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson 1Q U.S. Sales $13.33B >JNJ

2026-04-14 10:20; UTC

Uždarbis

Johnson & Johnson 1Q International Sales $10.73B >JNJ

Akcijų palyginimas

Kainos pokytis

Johnson and Johnson Prognozė

Kainos tikslas

By TipRanks

19.55% į viršų

12 mėnesių prognozė

Vidutinis 264.73 USD 19.55%

Aukščiausias 285 USD

Žemiausias 240 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Johnson and Johnson kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

17 ratings

Pirkti

Laikyti

Parduoti

Remiantis 17 analitikų, pateikusių Johnson and Johnson akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

154.93 / 155.895Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.